biomanbaba

biomanbaba
Send Message
View as an RSS Feed
  • Interview With Leo Ehrlich, Cellceutix CEO Following Acquisition Of PolyMedix Assets  [View article]
    Mr Sharvy

    Mr Ehrlichs transactions are not at all remarkable. We note you dont compare them to Anything other than some standard of your imagination and you fail to tell us what that is. Your goal here is clear
    and in my view smells like a dead skunk laying in the road.
    Sep 22, 2013. 09:12 AM | 4 Likes Like |Link to Comment
  • Five Years After Lehman, It's Business As Usual On Wall Street  [View article]
    Best writing I have seen since Gasparino "the Sellout". An additional issue remains that nobody has ever been prosecuted under Sarbanes- Oxley....Holder refused to appear on the Sixty minutes segment about that and sent a flunky to muddy the water instead of answer reporters questions. Naming any AG in my lifetime who really deserves respect is almost impossible. We need to directly elect the Attorney General of the United States.
    Sep 21, 2013. 01:00 AM | 1 Like Like |Link to Comment
  • Interview With Leo Ehrlich, Cellceutix CEO Following Acquisition Of PolyMedix Assets  [View article]
    Dear Docrog

    Wonderful lesson in the use of satire to make a point...I like your style
    Sep 19, 2013. 10:33 PM | 1 Like Like |Link to Comment
  • Interview With Leo Ehrlich, Cellceutix CEO Following Acquisition Of PolyMedix Assets  [View article]
    Bill

    There is no doubt about that. Rational investors all see it. The bulletin boards have become frothy lately and some there were looking for
    a short term blast off at ROTH. The daytraders didnt get their fix.
    Investors will buy what traders sell and normalcy will return
    Sep 18, 2013. 10:52 AM | 2 Likes Like |Link to Comment
  • Interview With Leo Ehrlich, Cellceutix CEO Following Acquisition Of PolyMedix Assets  [View article]
    KarinCA

    Thank you for once again adding value to shareholder understanding with this piece. I fould this remark very useful
    "we do not determine the dosing level or the pace of cohort completion; the Safety Review Committee and the IRB do, so we will have to wait until this cohort is complete to see what level they want to go to next." It will likely end irrational expectations on the bulletin boards about the pace at which dose escalation will proceed. When irrational expectations develop and are not met
    then great harm can occur. You have done your readers a service once again by adding clarity to the available due diligence on CTIX.
    2014 will be a very exciting time for CTIX as results sought by shareholders come into view. Investors who have their eyes on the prize will we rewarded for their patients as trial data begins to flow
    Sep 18, 2013. 09:31 AM | 3 Likes Like |Link to Comment
  • Intel's 14 Nanometer: It's Here And It Kicks Butt  [View article]
    so well done ashraf..........thank you
    Sep 17, 2013. 02:50 AM | Likes Like |Link to Comment
  • Nowhere Else To Go: Rising Rates Won't Be Enough To Curb Stocks  [View article]
    Mr Donaldson

    I would support your plan to let the mortgage bonds mature. Unfortunately you and I are not serving on the FOMC. Thank you for your response
    Aug 26, 2013. 11:33 AM | Likes Like |Link to Comment
  • Nowhere Else To Go: Rising Rates Won't Be Enough To Curb Stocks  [View article]
    Mr Donaldson

    You don't comment on Ben Bernankes pending retirement or the Detroit debacle. Perhaps you have elsewhere and I haven't seen that yet. How many more municipal environments collapse under even a modestly rising yield curve? What are the prospects that Bernankes replacement will be able to unwind the Fed balance sheet in a manner inspiring sufficient confidence to forestall a usurpation of interest rate policy by the bond market vigilantes.
    Pollyannas don't seem to be attentive to such dangers. I wonder if you are?
    Aug 22, 2013. 10:19 AM | Likes Like |Link to Comment
  • Celsion's CEO Thumbs His Nose At Short Sellers  [View article]
    I support your view. It appears that the Raven is simply trying to get himself out from being underwater. I burned the bridge and moved on. CTIX is the future and may infact replace current technology wholesale. CLSN is probably dead money
    Aug 17, 2013. 10:21 AM | Likes Like |Link to Comment
  • International Stem Cell Solves Immune Rejection Issue For Significant Segment Of Population  [View article]
    Pman701
    I agree with your sentiments. She should indeed keep doing what she is doing. A substantial portion of my understanding of this Monster investment opportunity is to her credit and I will be forever grateful.
    Few biotechs enter the clinic with a revenue stream as fantastic as we see here. The likely gains in the stem cell lines are somewhat blinded to us by the fact that many ISCO customers are currently privately held. Explosive sales gains can in fact come Out of the Blue.
    Aug 14, 2013. 09:08 AM | 2 Likes Like |Link to Comment
  • International Stem Cell Solves Immune Rejection Issue For Significant Segment Of Population  [View article]
    Dear Pman701

    Unfortunately many ISCO investors are in your position. I have told those who follow me that I believe this selloff represents the buying opportunity of a lifetime to average down and have a great basis in the likely sector leading firm in regenerative medicine. Their move into the clinic with a possible PD cure looms large. The is no better chance to turn pennies into dollars in biotech today in my opinon.
    Good luck with your investments
    Aug 13, 2013. 02:55 PM | 2 Likes Like |Link to Comment
  • Cirrus Logic Misses, But There's Still A Diversification Story  [View article]
    Ashraf.......is POETF a pardigm shift or a flash in the pan?
    Jul 29, 2013. 12:28 AM | Likes Like |Link to Comment
  • Cellceutix: Upcoming Significant Events And The Odds Of Success  [View article]
    luvkashyap
    I expect Dr Shapiro will indeed write a peer reviewed paper at trial end that will Ring Your Bell. In the short run your continued table pounding about the fact that it isnt published yet appears to be nothing more than mindless bashing
    Jul 25, 2013. 04:21 PM | 2 Likes Like |Link to Comment
  • A $180 Million Company Worth Less Than $0: Short Xumanii  [View article]
    Ashraf is our MAN in the silicon tech field and his work is a must read BUT Karin you have sent him to school on this subject
    Jul 23, 2013. 11:58 PM | 2 Likes Like |Link to Comment
  • A Small Biotech With Breakthrough Potential In Cancer Treatment  [View article]
    I am surprised you didnt make destinctions between DVAX-L and DCVAX-Direct I would reccommend reading Smith here
    http://bit.ly/12cE0Gk
    also adding the trial links would have increased the value of your
    work to new investors doing due diligence
    http://1.usa.gov/12cE34Y
    Then clinicaltrials.gov says the prostrate trial
    has been withdrawn?
    http://1.usa.gov/12cE0Gq
    Jul 22, 2013. 02:49 PM | 1 Like Like |Link to Comment
COMMENTS STATS
107 Comments
114 Likes